Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer

References

• Sung HA-O, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg. 1941;115(6):1192–1200.
   Google Scholar
• Karantanos T, Corn TC, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32(49):5501–5511.
   PubMed Web of Science ®Google Scholar
• Ruizeveld De Winter JA, Janssen PJ, Sleddens HM, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol. 1994;144(4):735–746.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sawyers HI, Fau - Scher C, et al. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8(4):440–448.
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469–5477.
   PubMed Web of Science ®Google Scholar
• Gottlieb B, Beitel LK, Wu JH, et al. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat. 2004;23(6):527–533.
   PubMed Web of Science ®Google Scholar
• Sun S, Sprenger CCT, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120(8):2715–2730.
   PubMed Web of Science ®Google Scholar
• Inoue T, Segawa T, Kamba T, et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology. 2009;73(5):1104–1109.
   PubMed Web of Science ®Google Scholar
• Kato I, Severson AG, Fau - Schwartz RK, et al. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer. 2001;C92(8):2211–2219.
   Google Scholar
• Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
   PubMed Web of Science ®Google Scholar
• Fabbri F, Amadori D, Carloni S, et al. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J Cell Physiol. 2008;217(2):494–501.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–5.
   PubMed Web of Science ®Google Scholar
• Marín-Aguilera M, Codony-Servat J, Kalko SG, et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther. 2012;11(2):329–339.
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J, Vidal S, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012;22(3):373–388.
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25–29.
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
   PubMed Web of Science ®Google Scholar
• Ogata H, Goto S, Sato K, et al. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999;27(1):29–34.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52.
   PubMed Web of Science ®Google Scholar
• Fau CC, Chen S-H. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;(Suppl 4):S11.
   PubMedGoogle Scholar
• Shannon P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110.
   PubMed Web of Science ®Google Scholar
• Mahon KL, Lin H-M, Castillo L, et al. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 2015;112(8):1340–1348.
   PubMed Web of Science ®Google Scholar
• West KA, Castillo PA, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002;5(6):234–248.
   PubMed Web of Science ®Google Scholar
• Fizazi K, De Bono JS, Flechon A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2012;48(1):85–93.
   PubMed Web of Science ®Google Scholar
• Duran GE, Wang YC, Francisco EB, et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14(1):193–201.
   PubMed Web of Science ®Google Scholar
• Galletti G, Matov A, Beltran H, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014;5(1):5548.
   PubMedGoogle Scholar
• Gottesman MM, Fojo SE, Bates SE. Bates, multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
   PubMed Web of Science ®Google Scholar
• Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–175.
   PubMed Web of Science ®Google Scholar
• Ludwig A, Petersen F, Zahn S, et al. The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2. Blood. 1997;90(11):4588–4597.
   PubMed Web of Science ®Google Scholar
• Sison EAR, McIntyre E, Magoon D, et al. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. Mol Cancer Res. 2013;11(9):1004–1016.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Xi Shi Y, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215–6224.
   PubMed Web of Science ®Google Scholar
• Hoofd C, Wang X, Lam S, et al. CD44 promotes chemoresistance in T-ALL by increased drug efflux. Exp Hematol. 2016;44(3):166–171.
   PubMed Web of Science ®Google Scholar
• Sun L, Fang Y, Wang X, et al. miR-302a inhibits metastasis and cetuximab resistance in colorectal cancer by targeting NFIB and CD44. Theranostics. 2019;9(26):8409–8425.
   PubMed Web of Science ®Google Scholar
• Wang Z, Qin J, Zhao J, et al. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Theranostics. 2020;10(16):7178–7192.
   PubMed Web of Science ®Google Scholar
• Abdelmoneem MA, Abd Elwakil MM, Khattab SN, et al. Lactoferrin-dual drug nanoconjugate: synergistic anti-tumor efficacy of docetaxel and the NF-κB inhibitor celastrol. Mater Sci Eng C Mater Biol Appl. 2021;118:111422.
   PubMed Web of Science ®Google Scholar
• Zheng CW. Rho GTPases: promising candidates for overcoming chemotherapeutic resistance. Cancer Lett. 2020;10:65–78.
   Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301–1309.
   PubMed Web of Science ®Google Scholar
• Feng Q. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1. Biochem Pharmacol. 2020;178:114092.
   PubMed Web of Science ®Google Scholar
• Liu R. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Montazeri H, Tarighi P. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with docetaxel on LNCaP prostate cancer cell line. Eur J Pharmacol. 2020;878:173102.
   PubMed Web of Science ®Google Scholar
• Xie B, Wang S, Jiang N, et al. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett. 2019;443:56–66.
   PubMed Web of Science ®Google Scholar
• Yoo GH, Piechocki MP, Oliver J, et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope. 2004;114(11):1871–1879.
   PubMed Web of Science ®Google Scholar
• Lee E, Decker AM, Cackowski FC, et al. Growth arrest-specific 6 (GAS6) promotes prostate cancer survival by G1 arrest/s phase delay and inhibition of apoptosis during chemotherapy in bone marrow. J Cell Biochem. 2016;117(12):2815–2824.
   PubMed Web of Science ®Google Scholar
• Giovinazzi S, Lindsay CR, Morozov VM, et al. Regulation of mitosis and taxane response by Daxx and Rassf1. Oncogene. 2012;31(1):13–26.
   PubMed Web of Science ®Google Scholar
• Nutt SL, Keenan C, Chopin M, et al. EZH2 function in immune cell development. Biol Chem. 2020;401(8):933–943.
   PubMed Web of Science ®Google Scholar
• Yao Y, Hu H, Yang Y, et al. Downregulation of enhancer of zeste homolog 2 (ezh2) is essential for the induction of autophagy and apoptosis in colorectal cancer cells. LID - 83. Genes. 2016;7(10):83.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wang W, Li B, et al. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells. BMC Cancer. 2019;19(1):27.
   PubMedGoogle Scholar
• Zhang Q, Padi SKR, Tindall DJ, et al. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis. 2014;5(10):e1486.
   PubMedGoogle Scholar
• Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017 Feb 28;387:61–68.
   PubMed Web of Science ®Google Scholar
• Wang D. Targeting EZH2 reprograms intratumoral regulatory t cells to enhance cancer immunity. Cell Rep. 2018;23(11):3262–3274.
   PubMed Web of Science ®Google Scholar
• Li H. Epigenetic modification of enhancer of zeste homolog 2 modulates the activation of dendritic cells in allergen immunotherapy. Int Arch Allergy Immunol. 2019;180(2):120–127.
   PubMed Web of Science ®Google Scholar
• Yin Y, Qiu S, Li X, et al. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment. J Neuroinflammation. 2017;14(1):220.
   PubMedGoogle Scholar